Serum-circulating His-tRNA synthetase inhibits organ-targeted immune responses
Ryan A. Adams(aTyr Pharma (United States)), Paul Schimmel(Scripps Research Institute), Antonella Notarnicola(Karolinska University Hospital), Cátia Fernandes‐Cerqueira(Karolinska University Hospital), John Mendlein(aTyr Pharma (United States)), Sanna Rosengren(AstraZeneca (Sweden)), Elisabeth Mertsching(aTyr Pharma (United States)), Kathleen M. Ogilvie(aTyr Pharma (United States)), Andrea Cubitt(aTyr Pharma (United States)), Zhiwen Xu(Sichuan Agricultural University), Leslie A. Nangle(aTyr Pharma (United States)), David J. King(AnaBios (United States)), Jeanette Ampudia(aTyr Pharma (United States)), Wing‐Sze Lo(Hong Kong University of Science and Technology), Kyle P. Chiang(aTyr Pharma (United States)), Xiang‐Lei Yang(Scripps Research Institute), Per‐Johan Jakobsson(Karolinska University Hospital), Ingrid E. Lundberg(Karolinska University Hospital)
Cited by 39
Related Papers
Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin
|Journal of Clinical Investigation|2012|708
High-Level Expression of a Recombinant Antibody from Myeloma Cells Using a Glutamine Synthetase Gene as an Amplifiable Selectable Marker
|Nature Biotechnology|1992|465
International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease
|Lara D. Veeken|2003|367
Activation of the endoplasmic reticulum stress response in autoimmune myositis: Potential role in muscle fiber damage and dysfunction
|Arthritis & Rheumatism|2005|345
A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody
|Molecular Immunology|1993|243